Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Piclozotan

Drug Profile

Piclozotan

Alternative Names: SUN 4057; SUN N 4057

Latest Information Update: 13 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharma
  • Class Anti-ischaemics; Neuroprotectants; Oxazepines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Dyskinesias
  • Discontinued Stroke

Most Recent Events

  • 13 May 2014 No development reported - Phase-II for Dyskinesia in USA, Guatemala & Romania (IV)
  • 11 Jun 2009 Pharmacodynamics data from a preclinical trial in Parkinson's disease presented at the 13th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2009)
  • 15 Jul 2008 Discontinued - Phase-II for Stroke in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top